CDK | Adooq Bioscience

Cat. No.: A25107

CAS No.: 2541626-49-5

PROTAC CDK2/4/6 Degrader-2

PROTAC CDK2/4/6 Degrader-2 is a targeted protein degradator specifically designed to degrade cyclin-dependent kinases CDK2, CDK4, and CDK6. This compound effectively inhibits cell proliferation and induces cell cycle arrest and apoptosis in malignant melanoma cells. Its application extends to cancer research, particularly in investigating the role of CDK2/4/6 in tumor biology. The compound can also be converted into its prodrug form, enabling versatile utilization in various assays related to cancer therapeutics.

View Details

Out of stock

All 3 sizes

Cat. No.: A30477

CAS No.: 3025082-14-5

PROTAC CDK4/6 degrader 1

PROTAC CDK4/6 degrader 1 is a dual-targeted degrader designed to selectively degrade cyclin-dependent kinases CDK4 and CDK6. With DC50 values of 10.5 nM and 2.5 nM, this compound effectively inhibits cell proliferation in Jurkat cells, demonstrating an IC50 of 0.18 μM. The compound promotes G1 phase cell cycle arrest and triggers apoptosis, making it a valuable tool for studying cancer biology and potential therapeutic applications in CDK-related malignancies.

In stock View Details

All 3 sizes

Cat. No.: A30493

CAS No.: 790245-61-3

NCT02

NCT02 is a molecular glue degrader that targets CDK12 through the E3 ubiquitin ligase DDB1, resulting in the ubiquitination and subsequent proteasomal degradation of its partner protein CCNK. This mechanism leads to the downregulation of CDK12, inhibiting its downstream signaling pathways. NCT02 exhibits significant biological activity by inducing apoptosis in tumor cells, arresting the cell cycle, and selectively inhibiting the proliferation of colorectal cancer cells with TP53 mutations or belonging to the CMS4 molecular subtype. Additionally, NCT02 demonstrates potential in suppressing tumor growth in both in vitro and in vivo models.

In stock View Details

2 mg

$50.00

5 mg

$100.00

All 6 sizes

Cat. No.: A30620

CAS No.: 3055471-57-0

CPD-10

CPD-10 is a targeted CCND1 and CDK4 PROTAC degrader that effectively promotes the degradation of these proteins. Exhibiting significant anti-proliferative activity, CPD-10 induces apoptosis in cancer cell lines. It decreases the expression levels of cyclin D1, cyclin D3, CDK4, and phosphorylated Rb at serines 5807 and 811 in a dose-dependent manner, making it a valuable tool for research in cancer biology and therapeutic applications targeting cell cycle regulation.

In stock View Details

1 mg

$480.00

5 mg

$1,230.00

All 5 sizes

Cat. No.: A30747

CAS No.: 2821803-61-4

HEMTAC CDK4/6 degrader 1

HEMTAC CDK4/6 degrader 1 is a PROTAC designed to target CDK4 and CDK6 through a dual-ligand approach involving HSP90. This compound effectively induces the degradation of CDK4/6 in B16F10 melanoma cells, leading to cell cycle arrest at the G0/G1 phase and subsequent apoptosis. It serves as a vital tool for cancer research, particularly in elucidating mechanisms of CDK4/6 regulation and their role in tumor progression. Additionally, HEMTAC CDK4/6 degrader 1 features an alkyne functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds for advanced applications in chemical biology.

In stock View Details

All 4 sizes

Cat. No.: A30989

CAS No.: 2809353-52-2

LL-K9-3

LL-K9-3 is a small-molecule degrader specifically targeting the CDK9-cyclin T1 complex. This compound exhibits significant anti-proliferative and pro-apoptotic activities, effectively inhibiting downstream signaling pathways associated with CDK9 and androgen receptor (AR). LL-K9-3 is particularly relevant for research involving oncogenic transcriptional programs driven by AR and Myc, making it a valuable tool in cancer studies.

In stock View Details

All 2 sizes

Cat. No.: A31180

CAS No.: 3032908-44-1

LA-CB1

LA-CB1 is a CDK4/6 degrader that promotes the degradation of cyclin-dependent kinases 4 and 6 through the ubiquitin-proteasome pathway. This action disrupts the CDK4/6-Cyclin D1-Rb-E2F signaling axis, leading to G0/G1 cell cycle arrest and apoptosis. LA-CB1 demonstrates potent anti-proliferative effects against MDA-MB-231 cells, with an IC50 of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition, cell migration, invasion, and angiogenesis. In models of triple-negative breast cancer, LA-CB1 significantly inhibits tumor growth in a dose-dependent manner, making it a valuable compound for research in breast cancer therapeutics.

In stock View Details

All 4 sizes

Cat. No.: A32667

CAS No.: 3064994-97-1

PROTAC CDK4/6/9 degrader 1

PROTAC CDK4/6/9 Degrader 1 is a targeted protein degradation agent that specifically degrades cyclin-dependent kinases CDK4, CDK6, and CDK9. This compound effectively inhibits the proliferation of triple-negative breast cancer (TNBC) cells by inducing G1 phase arrest, promoting apoptosis, and suppressing cellular migration and invasion. PROTAC CDK4/6/9 Degrader 1 serves as a valuable tool for studying the role of these kinases in TNBC and may support the development of novel therapeutic strategies aimed at this aggressive cancer subtype.

View Details

Out of stock

All 3 sizes

Cat. No.: A38459

CAS No.: 3052648-82-2

PROTAC CDK9 degrader-12

PROTAC CDK9 degrader-12 is a selective CDK9 degrader that utilizes the E3 ubiquitin ligase-mediated proteasomal pathway for the degradation of CDK9, exhibiting a DC50 of 23 nM. This compound effectively inhibits CDK9-mediated transcriptional elongation of HIV-1, subsequently reducing HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is designed for research applications focused on HIV-1 infection and the study of transcriptional regulation.

View Details

Out of stock

All 3 sizes

Cat. No.: A38460

CAS No.: 2980502-40-5

TR-213

TR-213 is a potent molecular glue degrader that specifically targets Cyclin K (CDK). At a concentration of 1 μM, TR-213 demonstrates a significant inhibition of CDK12 and Cyclin levels, leading to decreases of 91% and 56%, respectively. This compound effectively inhibits RNA polymerase II activity and modulates alternative polyadenylation (APA), making it a valuable tool for cancer research and investigations into CDK-related pathways.

View Details

Out of stock

All 3 sizes

Cat. No.: A46129

CAS No.: 3066836-42-5

CDK9 autophagic degrader 1

CDK9 autophagic degrader 1 is a selective autophagic degrader targeting cyclin-dependent kinase 9 (CDK9). This compound effectively degrades CDK9, leading to a significant reduction in associated Cyclin T1 levels. Demonstrating over 80% inhibition of CDK9 at a concentration of 100 nM, this reagent serves as a valuable tool for research applications focused on transcriptional regulation and cancer biology.

View Details

Out of stock

All 3 sizes

Cat. No.: A53679

CAS No.: 3054009-82-1

KI-CDK9d-32

KI-CDK9d-32 is a selective and potent degrader designed to target CDK9 through a PROTAC mechanism (DC50: 0.89 nM). It facilitates the ubiquitination and subsequent degradation of CDK9, effectively inhibiting the MYC signaling pathway and disrupting nucleolar homeostasis. This compound demonstrates significant anticancer activity, particularly against acute lymphoblastic leukemia and pancreatic cancer, making it a valuable tool for research in cancer biology and therapeutic development.

In stock View Details

1 mg

$360.00

5 mg

$900.00

All 5 sizes

Cat. No.: A54134

CAS No.: 1226443-41-9

HQ461

HQ461 is a molecular glue that facilitates the interaction between CDK12 and DDB1, leading to the targeted degradation of cyclin K. This degradation impairs CDK12 function, which in turn results in reduced phosphorylation of CDK12 substrates, downregulation of DNA damage response genes, and induces apoptosis in affected cells. HQ461 is a valuable tool for research applications focused on the modulation of cell cycle regulation and the DNA damage response pathway.

In stock View Details

1 mg

$30.00

2 mg

$45.00

All 8 sizes

Cat. No.: A54145

CAS No.: 3055472-38-0

CPD-39

CPD-39 is a potent heterobifunctional PROTAC degrader that targets CCND1 and CDK4. This compound effectively induces the degradation of these proteins, demonstrating significant anti-proliferative activity. CPD-39 is intended for research applications focusing on the modulation of cell cycle regulation and cancer therapeutics.

In stock View Details

All 4 sizes

Cat. No.: A54150

CAS No.: 3036606-92-2

CDK2 degrader 6

CDK2 degrader 6 is a potent CDK2 molecular glue degrader that functions through binding to cereblon and CDK2, leading to the ubiquitination and proteasomal degradation of CDK2. With a DC50 of 46.5 nM, it effectively modulates the cell cycle and reduces proliferation in breast cancer cells. Additionally, CDK2 degrader 6 demonstrates in vivo antitumor activity in gastric cancer mouse models, making it a valuable tool for research into breast and gastric cancers.

In stock View Details

All 3 sizes

Cat. No.: A54164

CAS No.: 2862772-71-0

CDK2 degrader 3

CDK2 Degrader 3 is a selective degrader of cyclin-dependent kinase 2 (CDK2) that promotes degradation of the target protein. This compound induces G1 cell cycle arrest specifically in CCNE1-amplified cancer cells, making it a valuable tool for studying cell cycle regulation. CDK2 Degrader 3 is particularly relevant for research applications related to breast cancer.

In stock View Details

All 2 sizes

Cat. No.: A54165

CAS No.: 3103763-70-5

JWZ-5-13

JWZ-5-13 is a potent CDK7 PROTAC degrader that selectively targets cyclin-dependent kinase 7 for ubiquitin-proteasome system-mediated degradation. It exhibits significant antiproliferative effects on various cancer cell lines, making it an essential tool for studying pathways involved in malignancies such as ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia, and non-small cell lung cancer. This compound facilitates the exploration of targeted protein degradation in cancer biology, offering insights into therapeutic strategies.

In stock View Details

5 mg

$715.00

10 mg

$1,170.00

All 5 sizes

Cat. No.: A54174

CAS No.: 2488892-09-5

TMX-2172

TMX-2172 is a selective bivalent PROTAC that targets CDK2 and CDK5, inducing their proteasomal degradation with IC50 values of 6.5 nM and 6.8 nM, respectively. This compound demonstrates notable selectivity for CDK2 and CDK5, while sparing other cyclin-dependent kinases such as CDK1, CDK4, CDK6, CDK7, and CDK9. TMX-2172 effectively inhibits the enzymatic activity of CDK2 and CDK5, leading to a reduction in ASCL1 protein levels, induction of cancer cell death, and antiproliferative effects. This reagent is applicable in research focused on ovarian cancer and small cell lung cancer.

In stock View Details

1 mg

$495.00

5 mg

$1,010.00

All 5 sizes

Cat. No.: A54175

CAS No.: 2519823-37-9

BSJ-5-63

BSJ-5-63 is a potent PROTAC degrader targeting CDK12, CDK7, and CDK9. It effectively reduces protein expression levels of these kinases as well as RNAPII and Cyclin K, resulting in decreased mRNA expression of BRCA1 and BRCA2. This compound exhibits significant anticancer activity and is particularly relevant for research focused on prostate cancer.

In stock View Details

5 mg

$160.00

10 mg

$230.00

All 5 sizes

Cat. No.: A54177

CAS No.: 2923574-11-0

CDK2 degrader 5

CDK2 Degrader 5 is a targeted degrader for cyclin-dependent kinase 2 (CDK2), achieving a maximum degradation (Dmax) of over 50% and up to 80% in the HiBiT Assay. This compound is integral for probing CDK2's role in cell cycle regulation and cancer biology, making it a valuable tool for researchers investigating therapeutic strategies in oncology. Its selective degradation mechanism allows for a deeper understanding of CDK2 functions in various cellular contexts.

In stock View Details

1 mg

$70.00

5 mg

$180.00

All 6 sizes

Cat. No.: A54184

CAS No.: 3053716-46-1

ZLC491

ZLC491 is a PROTAC degrader that selectively targets CDK12 and CDK13, utilizing cereblon- and proteasome-dependent mechanisms for degradation. This compound effectively inhibits the transcription and expression of long genes, particularly those involved in DNA damage response pathways. ZLC491 demonstrates anti-proliferative effects in various triple-negative breast cancer cell lines, making it a valuable tool for research into targeted therapies for this aggressive cancer subtype.

In stock View Details

5 mg

$295.00

10 mg

$505.00

All 5 sizes

Cat. No.: A54188

CAS No.: 3030279-55-8

CDK2 degrader 7

CDK2 Degrader 7 is an orally active compound that targets cyclin-dependent kinase 2 (CDK2) for selective degradation. It exhibits effective biological activity with DC50 values of 13 nM in MKN1 cells and 17 nM in TOV21G cells, leading to G1 phase arrest in MKN1 cells. Additionally, CDK2 Degrader 7 demonstrates efficacy in achieving tumor stasis in xenograft models of HCC1569 with CCNE1 amplification. This reagent is valuable for investigating the therapeutic potential in CCNE1-amplified cancers.

In stock View Details

1 mg

$260.00

5 mg

$670.00

All 5 sizes

Cat. No.: A54195

CAS No.: 3030271-16-7

CDK2 degrader 2

CDK2 Degrader 2 is a potent PROTAC targeting cyclin-dependent kinase 2 (CDK2), facilitating its degradation in MKN1 cells with a DC50 value of less than 100 nM. This compound employs a novel design, integrating a ligand for the target protein along with a linker and a ligand for the E3 ligase cereblon (CRBN). CDK2 Degrader 2 is valuable for research applications focused on the regulation of cell cycle progression and the exploration of targeted protein degradation mechanisms.

In stock View Details

All 3 sizes

Cat. No.: A54198

CAS No.: 2924122-01-8

CDK2 degrader 4

CDK2 Degrader 4 is a selective degrader that targets cyclin-dependent kinase 2 (CDK2). This compound promotes the degradation of CDK2, thereby inhibiting its activity in cell cycle regulation. CDK2 Degrader 4 is significant for cancer research, providing insights into CDK2's role in tumor growth and proliferation. Its application can aid in the development of targeted therapies for CDK2-dependent malignancies.

In stock View Details

All 4 sizes

Cat. No.: A54207

CAS No.: 3117192-80-7

PROTAC CDK9 degrader-9

PROTAC CDK9 degrader-9 is a selective and potent degrader designed to target cyclin-dependent kinase 9 (CDK9) via PROTAC technology. This compound facilitates the targeted degradation of CDK9, thereby modulating transcriptional regulation and influencing cell proliferation. It is particularly useful in anti-cancer research, where the inhibition of CDK9 can lead to suppression of oncogenic pathways.

In stock View Details

1 mg

$415.00

5 mg

$1,065.00

All 5 sizes